PTX — Prescient Therapeutics Income Statement
0.000.00%
- AU$32.21m
- AU$13.77m
- AU$0.46m
- 62
- 15
- 39
- 35
Annual income statement for Prescient Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.072 | 0.07 | 0.066 | 0.044 | 0.459 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3.9 | 3.41 | 4.19 | 5.21 | 7.46 |
Operating Profit | -3.83 | -3.34 | -4.13 | -5.17 | -7 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -3.8 | -3.32 | -4.15 | -5.12 | -7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -3.8 | -3.32 | -4.15 | -5.12 | -7 |
Net Income Before Extraordinary Items | |||||
Net Income | -3.8 | -3.32 | -4.15 | -5.12 | -7 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -3.8 | -3.32 | -4.15 | -5.12 | -7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.016 | -0.009 | -0.007 | -0.008 | -0.01 |